Teva and Active Biotech discontine high doses of laquinimod in two ongoing studies in multiple sclerosis after the occurrence of cardiovascular events, none of which was fatal, in eight patients; CONCERTO and ARPEGGIO Trials Continue Study
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?